← Issue №17/ week of Oct 25, 2026/Nutrition

Association between augmented enteral protein and muscle mass attenuation in critically ill patients: A sub-study of a cluster randomized crossover trial.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Nutrition rct · n=72 · Oct 21, 2026 · JPEN · IF 3.2

Association between augmented enteral protein and muscle mass attenuation in critically ill patients: A sub-study of a cluster randomized crossover trial.

New evidenceenteral nutritionbasic sciencetranslationalbiomarker
Clinical takeawayNo clinical action yet: this sub-study in critically ill patients found no clear benefit of augmented protein on muscle preservation over 7 days, though it was associated with greater right handgrip strength at ICU discharge (6.23; 95% CI, 0.67, 11.79) and greater decline in physical function at ICU discharge (-15.00; 95% CI, -19.75, -10.25).
What it foundAugmented enteral protein (100 g/L) vs usual protein (63 g/L) showed no difference in quadriceps muscle layer thickness change over 7 days (0.01 cm; 95% CI, -0.27, 0.28; P = 0.970).
ContextChallenges the hypothesis that higher protein intake preserves muscle mass in critically ill patients, contrasting with some prior observational data suggesting benefit.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Summers MJ … Chapple LS · JPEN. Journal of Parenteral and Enteral Nutrition · IF 3.2 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues